ilmscore | Prediction Details
"the management's target is to achieve 15 to 20% revenue growth and 28 to 30% EBITDA margin in the next 2 to 3 years."
By Groww | November 21, 2025 | Pending
From video
FII and DII are buying these 3 stocks? 00:12:11 - 00:12:18
Interpreted Prediction
SIL Life Sciences management targets 15-20% revenue growth and 28-30% EBITDA margin within the next 2-3 years.

Prediction Details

Topic
SIL Life Sciences

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.